Life Biosciences said its first human cellular reprogramming trial for glaucoma was well-tolerated in three patients, with no major side effects reported and vision improvements seen in two of them.
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
